ArticleMolecular cancer therapeutics2021

ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma.

Kelly E Henry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.